In this commentary for In the Pipeline, Derek Lowe highlights the results from a recent FDA report showing that the vast majority of all drugs that enter clinical trials fail. About 90% of compounds that start in the clinic never make it out; even among drugs that make it to Phase III of research, the failure rate is still almost 40%.
